• 1
    Costa MB, Andrade Ezequiel DG, Morais Lovis JC, et al. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome. J Clin Hypertens (Greenwich). 2010;12:753755.
  • 2
    Polyzos SA, Kountouras J, Zafeiriadou E, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;Epub ahead of print (DOI: 10.1177/1470320311402110).
  • 3
    Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;72:299314.
  • 4
    Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010;151:20402049.
  • 5
    Yutaka M, Mifune M, Kubota E, et al. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. Clin Exp Hypertens. 2009;31:648656.
  • 6
    Jeunemaitre X, Charru A, Chatellier G, et al. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. Am J Cardiol. 1988;62:10721077.
  • 7
    Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213:2730.
  • 8
    Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism. 2006;55:16451652.
  • 9
    Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005;28:4953.
  • 10
    Kebapcilar L, Taner CE, Kebapcilar AG, et al. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009 ( Epub ahead of print).
  • 11
    Nakhjavani M, Hamidi S, Esteghamati A, et al. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. Br J Clin Pharmacol. 2009;68:634637.
  • 12
    Studen KB, Sebestjen M, Pfeifer M, et al. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164:389395.
  • 13
    Garca PJ, Miranda ME, Mateos F, et al. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol. 1991;31:455461.
  • 14
    Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008;14:985992.
  • 15
    Mehdi UF, ms-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:26412650.
  • 16
    Bomback AS, Muskala P, Bald E, et al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin Nephrol. 2009;72:449456.
  • 17
    Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370376.